Core Viewpoint - The continuous rise of Hong Kong stocks since early September is driven by ample liquidity and ongoing investments and innovations in AI [1] Group 1: Market Dynamics - Southbound capital is expected to continue flowing into Hong Kong stocks due to the "wealth effect" [1] - The anticipated election of high-profile candidates, such as the potential new Japanese Prime Minister, could lead to arbitrage trading by Japanese investors benefiting Hong Kong stocks [1] Group 2: AI and Technology Sector - Increased capital expenditure by domestic and international companies in the AI sector, along with continuous iterations and innovations in large models and applications, may lead to performance realization in Hong Kong's complete AI and technology industry chain [1] - Despite a six-month valuation expansion, the current absolute valuation of Hong Kong stocks is not cheap [1] Group 3: Future Outlook - The fundamentals are expected to rebound, and with projected high growth in earnings by 2026, Hong Kong stocks remain significantly attractive on a global scale [1] - The report predicts that the long bull market for Hong Kong stocks since early 2024 will continue, driven by liquidity spillover effects and sustained AI narratives [1] Group 4: Investment Recommendations - Investors are advised to focus on four long-term directions: 1. Technology sector, including AI-related sub-sectors and consumer electronics [1] 2. Healthcare sector, particularly biotechnology [1] 3. Non-ferrous metals benefiting from rising overseas inflation expectations and de-dollarization [1] 4. Consumer sector, which may see valuation recovery amid further domestic economic recovery [1]

Core Viewpoint - The continuous rise of Hong Kong stocks since early September is driven by abundant liquidity and ongoing investments and innovations in AI [1] Group 1: Market Dynamics - Southbound capital is expected to continue flowing into Hong Kong stocks due to the "wealth effect" [1] - The potential election of a new Japanese Prime Minister, if successful, may lead to arbitrage trading by Japanese investors benefiting Hong Kong stocks [1] Group 2: Sector Analysis - Increased capital expenditure in the AI sector by domestic and international companies is anticipated to lead to performance realization in Hong Kong's complete AI and technology industry chain [1] - Despite a six-month valuation expansion, the current absolute valuation of Hong Kong stocks is not cheap, but the fundamentals are expected to rebound [1] Group 3: Investment Recommendations - Investors are advised to focus on four long-term directions: 1) Technology sector, including AI-related sub-sectors and consumer electronics [1] 2) Healthcare sector, particularly biotechnology [1] 3) Non-ferrous metals benefiting from rising overseas inflation expectations and de-dollarization [1] 4) Consumer sector, which may see valuation recovery with further domestic economic recovery [1]

Core Viewpoint - The company, Shanghai Youningwei Biotechnology Co., Ltd., has announced the use of idle self-owned funds for cash management, with a total limit of RMB 180 million, to enhance fund utilization efficiency and generate investment returns [1][6]. Group 1: Cash Management Plan - The company approved the use of up to RMB 30 million of idle raised funds and up to RMB 150 million of self-owned funds for cash management, effective for 12 months starting from March 9, 2025 [1]. - The cash management will involve low-risk investment products such as structured deposits and notice deposits [2][3]. Group 2: Risk Control Measures - The finance department will analyze and monitor the cash management products closely, maintaining communication with financial institutions to ensure fund safety [3]. - The internal audit department will conduct regular audits and verifications of the cash management fund usage [4]. Group 3: Impact on Daily Operations - The cash management initiative is designed to ensure the safety of the principal and will not affect the company's normal operations, aiming to improve fund efficiency and enhance company performance [6]. - The company has a history of using idle funds for cash management, with an outstanding balance of RMB 87.6 million in self-owned funds for structured deposits as of September 30, 2025 [7].

Market Overview - The global capital and financial markets have undergone a reshuffle during the extended National Day holiday, with significant events such as the U.S. government shutdown, Japan's stock market leading gains, and gold prices hitting historical highs [1] Stock Market Performance - Japanese stock market, particularly the Nikkei 225 index, reached a historical high by surpassing 48,000 points on October 6, driven by the election of a new party president [2] - The South Korean Composite Index rose by 3.6%, while the Australian S&P 200 Index increased by 1.12% [2] - The Hong Kong Hang Seng Index experienced a decline of 1.15% after initially rising during the holiday [2] - European markets also saw gains, with Germany's DAX index up by 2.11%, the UK's FTSE 100 up by 1.42%, and France's CAC40 up by 1.0% [2] U.S. Market Highlights - U.S. stock indices showed slight increases, with the Nasdaq up by 0.57%, the Dow Jones up by 0.44%, and the S&P 500 up by 0.39% [4] - The Philadelphia Semiconductor Index rose by 4.16% due to a significant agreement between AMD and OpenAI for a 6 GW chip supply, with AMD's stock experiencing a peak increase of over 30% [4] Gold Market Insights - Gold prices surged, with spot gold breaking the $4,000 mark for the first time, reflecting a year-to-date increase of nearly $1,400 per ounce, or over 52% [6] - UBS forecasts a bullish trend in the gold market, predicting prices could reach $4,200 per ounce by mid-2026, while Goldman Sachs raised its 2026 price estimate to $4,900 per ounce [6] Policy and Economic Measures - The People's Bank of China announced a significant liquidity injection of 1.1 trillion yuan through a buyout reverse repo operation, marking a high point in recent years [8] - The Chinese government introduced a policy to provide a 20% price evaluation discount for domestically produced products in government procurement, effective from January 1, 2026 [9] Automotive Industry Trends - The new energy vehicle sector saw a record high in charging volume during the holiday, with BYD reporting a decline in September sales to 396,300 units, while competitors like NIO and Xpeng achieved record deliveries [10] Technology Sector Developments - Meta's AI glasses have sold out in retail stores, indicating strong market demand, with plans for increased sales points and potential online ordering options [12] - Longfeng Pharmaceutical's stock surged over 230% on its debut, reflecting investor interest in the biotech sector amid a broader market downturn [13] Investment Outlook - Private equity firms maintain an optimistic outlook for the A-share market post-holiday, focusing on technology growth as a core investment theme [14] - October's "golden stocks" list from brokers highlights nearly 200 stocks, with a focus on technology growth and consumer recovery as key investment areas [15]

Core Insights - The Global X China Biotechnology ETF (02820) recorded positive returns in August, driven by globalization themes, domestic policy support, improved corporate earnings, and a favorable macro environment [1] - Significant foreign licensing transactions highlight global recognition of the innovation quality of Chinese companies, with an accelerating trend in the number and upfront payment amounts for such transactions over the past two years [1] - The Chinese biotechnology sector is expected to continue being a strong performer in 2023, with improved investor sentiment towards the healthcare sector due to enhanced earnings and commercialization processes [1] Industry Summary - The Chinese biopharmaceutical industry is being propelled by high-quality technology empowerment and policy support, as emphasized by the Chinese Premier during a recent visit [1] - The National Healthcare Security Administration has released a final list of drugs eligible for negotiation, with domestic biotech companies optimistic about upcoming negotiations becoming more favorable and flexible [1] - Reports indicate that the U.S. government is drafting an executive order to restrict Chinese pharmaceuticals and innovative therapies, but Chinese biotech firms may demonstrate resilience due to their capabilities in conducting global clinical trials [2] Company Analysis - Jiangsu Hengrui Medicine (01276) reported Q2 2025 revenue of 8.6 billion RMB (up 12.5% YoY) and a net profit of 2.6 billion RMB (up 25% YoY), with significant contributions from recent IPOs and licensing agreements [3] - Hengrui's new revenue growth point comes from collaboration income, including a licensing agreement with Merck that generated approximately 1.5 billion RMB [3] - Hengrui's recent licensing agreement with Braveheart Bio includes a $65 million upfront payment and potential milestone payments, indicating a strong pipeline for future licensing income [3] - BeiGene (06160) reported Q2 2025 revenue of $1.3 billion (up 18% QoQ) and a net profit of $94.3 million, exceeding market expectations, driven by strong sales of its product BRUKINSA [4] - BeiGene announced a deal with Royalty Pharma to sell sales-sharing rights for its anti-tumor drug IMDELLTRA outside China for up to $950 million, enhancing its cash reserves for future opportunities [4] - The Global X China Biotechnology ETF (02820) invests in 30 companies primarily engaged in the research, development, manufacturing, and distribution of biopharmaceuticals [4]

澳大利亚著名投资机构Simply Wall St发布报告指，和铂医药的收益在过去一年里飙升了243%，超过了 整个行业4.1%的平均增速。尽管盈利表现令人印象深刻，但其23倍的市盈率仍低于生物科技行业52倍 的平均水平，未来增长潜力巨大。该公司近期通过配股筹集了5.17亿港元的资金，并回购了1.21亿港元 的股票。截至2025年6月，和铂医药的股东权益为正数，自由现金流为4900万美元，公司已准备好继续 保持财务稳定。 和铂医药此前公布的中期业绩显示，截至2025年6月30日，上半年总收入约7.25亿元，同比增长327%； 盈利约5.23亿元，同比增长51倍。基于创新产品的对外授权与合作，为公司的收入增长做出了重要贡 献，并逐步成为公司的常态化收入来源。依托行业领先的Harbour Mice®技术平台及由其延展的2.0版本 技术平台体系，和铂医药已建立了强大的全球合作生态，成为全球抗体药物开发的"新基建"。 ...

Group 1 - The core viewpoint is that the current market rally is driven by strong corporate earnings rather than liquidity, indicating a shift from a "liquidity bull market" to an "earnings bull market" [3][6][20] - Corporate earnings have stabilized for three consecutive quarters, with the "Earnings Revision Breadth" indicator turning positive for the MSCI China Index in August, signaling a recovery in companies' profit-generating capabilities [4][25] - The market is experiencing significant internal differentiation, with hot sectors like technology, internet, finance, and biotechnology showing strong earnings growth, while traditional sectors like consumer goods and real estate are facing downward revisions [7][11][29] Group 2 - AI is not a bubble; leading companies in China are significantly undervalued compared to their U.S. counterparts, with the potential for substantial profit contributions from AI integration into their existing businesses [12][13][25] - The market is witnessing a fundamental shift in foreign investment, with over 90% of U.S. investors expressing plans to increase exposure to Chinese stocks, particularly in sectors where China has established global leadership [14][30] - Key sectors attracting foreign investment include humanoid robotics, automation, and biotechnology, indicating a strategic shift in how foreign investors view China from a mere emerging market to a core asset in the global tech race [15][16][30]

Market Sentiment - Current market sentiment reflects a sense of euphoria, with discussions around a potential bubble in the market, although this sentiment may continue to grow before any downturn occurs [2][3][4] - The market is compared to late 1999, suggesting that there may still be significant upside potential before a correction happens [3][4] Investment Strategy - The investment strategy should focus on maintaining positions in winning stocks while diversifying into sectors that have not yet led the rally, particularly healthcare [8][9][10] - Smaller cap names and sectors like healthcare are expected to contribute to the next leg of the market rally, as they have recently started to show positive momentum [6][7][10] Sector Analysis - Healthcare is highlighted as a promising sector for growth, with potential for significant returns as it has not participated in the rally to the same extent as other sectors [9][12] - The current market environment favors growth over value, indicating that investors are likely to seek opportunities in growth sectors like healthcare [12]

Core Insights - MIRXES-B (02629) has entered into a joint venture agreement with Xeraya Opportunities Fund PCC Limited to establish MYRNA DIAGNOSTICS SDN.BHD, with Mirxes holding 40% and Xeraya 60% of the equity [1] - The joint venture aims to address the urgent need for early cancer detection and other nucleic acid-based testing in Malaysia, a country facing a significant cancer burden [1][2] Company Strategy - The joint venture will leverage Xeraya's regional expertise in life sciences and healthcare to create a leading cancer omics platform in Malaysia, focusing on advanced miRNA-based multi-omics technology and validated blood cancer early detection [3] - The company plans to establish a localized omics testing business to enhance turnaround time and cost-effectiveness for existing clinical operations, while expanding into new market segments, including public healthcare institutions [3] - The strategy includes utilizing Malaysia's thriving biotech ecosystem to accelerate the development of clinical pipelines for colorectal, breast, liver, and multi-cancer types [3] - The joint venture aims to integrate R&D and clinical operations across Singapore, China, and Malaysia to expedite regulatory approvals for in vitro diagnostics (IVDs) and laboratory-developed tests (LDTs) [3] - The company envisions establishing a scalable regional platform in Malaysia as a springboard for expansion into neighboring ASEAN countries and other Asian markets with similar epidemiological characteristics and unmet screening needs [3] Industry Context - Malaysia, with a population exceeding 35 million, is facing a rising cancer burden, with over 51,650 new cancer cases and 31,633 cancer deaths reported in 2022 [2] - More than 60% of cancer cases in Malaysia are diagnosed at advanced stages (Stage III or IV), which severely limits patient survival outcomes and places a heavy burden on the healthcare system [2] - The cancer incidence rate in Malaysia is projected to increase by over 70% by 2050, highlighting the critical unmet need for early detection, particularly for high-incidence cancers such as lung, colorectal, breast, liver, and stomach cancers, which together account for nearly 50% of total cases [2]

消息面上，帝国科技集团公布，配售最多7464.85万股新股，配售价0.845港元，较10月2日收市价折让 19.52%，配售事项所得净额6235万港元，拟将用于直接及/或间接投资于开发人工智能技术，以支援集 团的现有业务；潜在直接或间接投资于已识别的商业应用AI解决方案提供商，包括生物科技；用于集 团的一般营运资金及一般企业用途。 格隆汇10月6日｜帝国科技集团(0776.HK)今日盘中一度大涨49.1%至2.49港元，股价创今年3月6日以来 约7个月新高；该股近两个交易日股价实现翻倍。 来源：格隆汇APP ...